Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology.

Frailty Glioblastoma KPS Meningioma Outcomes

Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 05 07 2023
accepted: 06 08 2023
pubmed: 25 8 2023
medline: 25 8 2023
entrez: 25 8 2023
Statut: ppublish

Résumé

Frailty has gained prominence in neurosurgical oncology, with more studies exploring its relationship to postoperative outcomes in brain tumor patients. As this body of literature continues to grow, concisely reviewing recent developments in the field is necessary. Here we provide a systematic review of frailty in brain tumor patients subdivided by tumor type, incorporating both modern frailty indices and traditional Karnofsky Performance Status (KPS) metrics. Systematic literature review was performed using PRISMA guidelines. PubMed and Google Scholar were queried for articles related to frailty, KPS, and brain tumor outcomes. Only articles describing novel associations between frailty or KPS and primary intracranial tumors were included. After exclusion criteria, systematic review yielded 52 publications. Amongst malignant lesions, 16 studies focused on glioblastoma. Amongst benign tumors, 13 focused on meningiomas, and 6 focused on vestibular schwannomas. Seventeen studies grouped all brain tumor patients together. Seven studies incorporated both frailty indices and KPS into their analyses. Studies correlated frailty with various postoperative outcomes, including complications and mortality. Our review identified several patterns of overall postsurgical outcomes reporting for patients with brain tumors and frailty. To date, reviews of frailty in patients with brain tumors have been largely limited to certain frailty indices, analyzing all patients together regardless of lesion etiology. Although this technique is beneficial in providing a general overview of frailty's use for brain tumor patients, given each tumor pathology has its own unique etiology, this combined approach potentially neglects key nuances governing frailty's use and prognostic value.

Identifiants

pubmed: 37624530
doi: 10.1007/s11060-023-04416-1
pii: 10.1007/s11060-023-04416-1
pmc: PMC10522517
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-308

Informations de copyright

© 2023. The Author(s).

Références

World Neurosurg. 2022 May;161:e572-e579
pubmed: 35196588
J Neurosci Nurs. 2022 Dec 1;54(6):240-244
pubmed: 36044724
Front Oncol. 2022 May 26;12:900382
pubmed: 35692808
World Neurosurg. 2022 Oct;166:268-278.e8
pubmed: 35843574
J Neurosurg. 2020 Aug 14;135(1):78-86
pubmed: 32796147
J Neurooncol. 2022 Nov;160(2):285-297
pubmed: 36316568
Clin Neurol Neurosurg. 2022 Nov;222:107445
pubmed: 36174406
J Clin Neurosci. 2020 Nov;81:95-100
pubmed: 33222979
Laryngoscope. 2021 Sep;131(9):1977-1984
pubmed: 33645657
Neurosurg Focus. 2020 Oct;49(4):E14
pubmed: 33002866
Otol Neurotol. 2020 Dec;41(10):e1243-e1249
pubmed: 32890290
Pituitary. 2020 Dec;23(6):630-640
pubmed: 32725418
World Neurosurg. 2021 Feb;146:e786-e798
pubmed: 33181381
J Neurol Surg B Skull Base. 2021 Oct 12;83(4):411-417
pubmed: 35903656
Biomedicines. 2022 Mar 10;10(3):
pubmed: 35327445
J Surg Res. 2013 Jul;183(1):104-10
pubmed: 23415494
World Neurosurg. 2019 Jun;126:e869-e877
pubmed: 30862575
World Neurosurg. 2018 Nov;119:e167-e173
pubmed: 30031190
J Clin Neurosci. 2019 Sep;67:5-9
pubmed: 31208835
Neuro Oncol. 2018 Jan 22;20(2):174-183
pubmed: 29016815
J Neurooncol. 2022 Dec;160(3):611-618
pubmed: 36394717
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Neurosurgery. 2020 Dec 15;88(1):147-154
pubmed: 32803222
J Clin Neurosci. 2019 Sep;67:1-4
pubmed: 31227406
World Neurosurg. 2020 Jan;133:e813-e818
pubmed: 31605842
World Neurosurg. 2022 Mar;159:e130-e138
pubmed: 34896348
J Neurooncol. 2018 Jan;136(1):197-206
pubmed: 29139096
J Neurosurg. 2022 Mar 11;:1-9
pubmed: 35353473
World Neurosurg. 2021 Feb;146:e865-e875
pubmed: 33197633
Eur J Surg Oncol. 2022 Jul;48(7):1671-1677
pubmed: 35216859
World Neurosurg. 2022 Oct;166:e949-e957
pubmed: 35948225
Diagnostics (Basel). 2022 Jan 29;12(2):
pubmed: 35204442
CA Cancer J Clin. 2021 Sep;71(5):381-406
pubmed: 34427324
J Neurooncol. 2022 May;158(1):15-22
pubmed: 35467234
J Am Coll Surg. 2010 Jun;210(6):901-8
pubmed: 20510798
Neurosurgery. 2022 Sep 1;91(3):477-484
pubmed: 35876679
EBioMedicine. 2019 Mar;41:683-692
pubmed: 30737084
J Neurooncol. 2020 Sep;149(3):421-427
pubmed: 32989681
JAMA Otolaryngol Head Neck Surg. 2021 Jul 1;147(7):608-614
pubmed: 33914061
World Neurosurg. 2016 May;89:362-7
pubmed: 26775233
J Am Coll Surg. 2018 Feb;226(2):173-181.e8
pubmed: 29155268
Neurosurg Focus. 2020 Oct;49(4):E15
pubmed: 33002865
J Geriatr Oncol. 2016 Nov;7(6):453-456
pubmed: 27478132
Clin Neurol Neurosurg. 2020 Oct;197:106192
pubmed: 32916396
J Geriatr Oncol. 2019 Sep;10(5):770-778
pubmed: 31005645
Circulation. 2010 Mar 2;121(8):973-8
pubmed: 20159833
Neurosurg Rev. 2022 Dec;45(6):3619-3628
pubmed: 36350492
J Geriatr Oncol. 2020 May;11(4):694-700
pubmed: 31704036
J Neurooncol. 2021 Dec;155(3):255-264
pubmed: 34626296
Front Neurol. 2021 Nov 30;12:777120
pubmed: 34917020
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Oper Neurosurg (Hagerstown). 2021 Aug 16;21(3):104-110
pubmed: 34038941
Surgery. 2021 Dec;170(6):1763-1769
pubmed: 34187694
J Neurooncol. 2020 Sep;149(3):429-436
pubmed: 32964354
J Neurooncol. 2021 Oct;155(1):45-52
pubmed: 34495456
Neurosurgery. 2022 Aug 1;91(2):312-321
pubmed: 35411872
Neurosurg Focus. 2018 Apr;44(4):E14
pubmed: 29606047
World Neurosurg. 2020 Oct;142:e344-e349
pubmed: 32652275
World Neurosurg. 2021 Sep;153:e338-e348
pubmed: 34217859
Cancers (Basel). 2022 Jun 22;14(13):
pubmed: 35804838
J Clin Neurosci. 2022 May;99:82-88
pubmed: 35278933
World Neurosurg. 2021 Feb;146:e1045-e1053
pubmed: 33242665
Am J Cancer Res. 2021 Jun 15;11(6):3294-3303
pubmed: 34249463
Neurosurg Focus. 2020 Oct;49(4):E16
pubmed: 33002880
Neurosurg Rev. 2022 Feb;45(1):617-626
pubmed: 34117561

Auteurs

Hanya M Qureshi (HM)

Department of Neurological Surgery, University of Massachusetts Medical School, Worcester, MA, USA.
Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Joanna K Tabor (JK)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Kiley Pickens (K)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Haoyi Lei (H)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Sagar Vasandani (S)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Muhammad I Jalal (MI)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Shaurey Vetsa (S)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Aladine Elsamadicy (A)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Neelan Marianayagam (N)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Brianna C Theriault (BC)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Robert K Fulbright (RK)

The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.
Yale School of Public Health, New Haven, CT, USA.

Ruihan Qin (R)

The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.
Yale School of Public Health, New Haven, CT, USA.

Jiarui Yan (J)

The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.
Yale School of Public Health, New Haven, CT, USA.

Lan Jin (L)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Joseph O'Brien (J)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Saul F Morales-Valero (SF)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA.

Jennifer Moliterno (J)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA. jennifer.moliternogunel@yale.edu.
The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, CT, USA. jennifer.moliternogunel@yale.edu.

Classifications MeSH